The addition of early and empirical high-dose cryoprecipitate to usual care does not improve clinical outcomes in patients with trauma and bleeding who required activation of a major hemorrhage ...
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for the Company’s ...
The Centre for Trauma Sciences, based at Queen Mary University of London, aims to reduce deaths from severe bleeding after major trauma. Having originally identified that trauma patients develop a ...
Two newer approaches to management of major hemorrhage missed the mark in randomized clinical trials published in a special transfusion-related issue of JAMA. In the CRYOSTAT-2 trial, adding early, ...
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced today that the Company has submitted a pre-market approval supplement (PMA-S) to the FDA for a pathogen reduced ...
Plasma from whole blood donations or apheresis is used to either prepare plasma components for clinical transfusion or fractionate to produce pure plasma proteins. Cryoprecipitate is produced by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results